Association of Papillary Thyroid Carcinoma with Primary Aldosteronism.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Feb 2019
Historique:
pubmed: 20 10 2018
medline: 23 4 2019
entrez: 19 10 2018
Statut: ppublish

Résumé

Objective The association of primary aldosteronism (PA) with thyroid disease has already been suggested. The aim of this study was to examine the presence of PA in patients with papillary thyroid carcinoma (PC) and to characterize such PC patients with PA. Methods We examined the presence of PA in 81 consecutive patients with PC, whose random sitting blood pressure (BP) was ≥140/90 mmHg in the office (n= 68), who had an incidental adrenal tumor or adrenal enlargement (n=9), or who showed hypokalemia (n=4). Thirty-one of these 81 patients had been treated with anti-hypertensive drugs. The plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were first measured before operation in 16 patients and after operation in 65 patients. PA was diagnosed according to the guidelines of the Japan Endocrine Society. Results Forty patients with PC with a random PAC/PRA ratio of over 200 were subjected to a further study (12 of these patients had been treated with anti-hypertensive drugs). Ultimately, 15 patients with PC were diagnosed with PA. Adrenal venous sampling was done in 9 out of 15 patients with PC associated with PA. No patients were diagnosed as having unilateral lesions. Among the 15 patients, white-coat hypertension was observed in 5 patients, and normotension was observed in 1 patient. Conclusion These findings suggest that the prevalence of PA may be high among patients with PC. An active examination is needed to detect PA, as its signs and symptoms may be mild in patients with PC associated with hypertension.

Identifiants

pubmed: 30333389
doi: 10.2169/internalmedicine.0891-18
pmc: PMC6421148
doi:

Substances chimiques

Biomarkers 0
Aldosterone 4964P6T9RB
Renin EC 3.4.23.15

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-504

Références

Mol Pathol. 2001 Jun;54(3):121-4
pubmed: 11376121
Cell. 2002 Oct 4;111(1):41-50
pubmed: 12372299
J Clin Endocrinol Metab. 2003 Jun;88(6):2489-94
pubmed: 12788844
Endocrine. 2003 Nov;22(2):155-60
pubmed: 14665720
Hypertens Res. 2004 Mar;27(3):193-202
pubmed: 15080378
Science. 2005 May 13;308(5724):1043-5
pubmed: 15845877
Recenti Prog Med. 2005 Jul-Aug;96(7-8):352-6
pubmed: 16209115
Eur J Endocrinol. 2005 Nov;153(5):637-42
pubmed: 16260421
J Clin Endocrinol Metab. 2006 Feb;91(2):454-9
pubmed: 16291704
J Clin Endocrinol Metab. 2006 Sep;91(9):3457-63
pubmed: 16822818
Clin Endocrinol (Oxf). 2007 Jun;66(6):886-9
pubmed: 17437517
Am J Hypertens. 2007 Aug;20(8):855-61
pubmed: 17679033
Clin Endocrinol (Oxf). 2008 Jul;69(1):20-8
pubmed: 18284637
Thyroid. 2008 Apr;18(4):461-4
pubmed: 18346005
Metab Syndr Relat Disord. 2009 Aug;7(4):375-80
pubmed: 19320560
Eur J Endocrinol. 2009 Oct;161(4):599-605
pubmed: 19633072
J Immunol. 2010 Jan 1;184(1):191-202
pubmed: 19949098
Nat Med. 2010 Jan;16(1):67-74
pubmed: 20023637
Hepatol Res. 2010 May;40(5):540-9
pubmed: 20412330
Nature. 2010 Jul 29;466(7306):627-31
pubmed: 20562852
Scand J Immunol. 2010 Sep;72(3):250-5
pubmed: 20696023
Hypertens Res. 2011 Jan;34(1):98-102
pubmed: 20927116
Mol Carcinog. 2011 Feb;50(2):123-35
pubmed: 21229609
Eur J Endocrinol. 2011 May;164(5):751-8
pubmed: 21357289
Rheumatol Int. 2012 Aug;32(8):2561-3
pubmed: 21789613
J Hypertens. 2011 Sep;29(9):1684-92
pubmed: 21826023
Endocr J. 2011;58(9):711-21
pubmed: 21828936
Am J Hypertens. 2011 Dec;24(12):1274-9
pubmed: 21850059
J Clin Endocrinol Metab. 2011 Dec;96(12):3615-27
pubmed: 21917876
Rare Tumors. 2011 Oct 21;3(4):e45
pubmed: 22355500
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):485-95
pubmed: 22863390
Biol Pharm Bull. 2012;35(9):1385-91
pubmed: 22975484
J Clin Endocrinol Metab. 2013 Nov;98(11):4446-56
pubmed: 23979949
Endocr J. 2014;61(1):35-40
pubmed: 24077222
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
Thyroid. 2014 Jul;24(7):1107-14
pubmed: 24708347
Int J Exp Pathol. 2014 Aug;95(4):244-50
pubmed: 24802662
Toxicol Appl Pharmacol. 2014 Nov 1;280(3):399-407
pubmed: 25204689
Curr Opin Nephrol Hypertens. 2015 Mar;24(2):139-44
pubmed: 25587902
Physiol Res. 2016 Jun 20;65(2):229-37
pubmed: 26447510
J Clin Endocrinol Metab. 2016 Apr;101(4):1656-63
pubmed: 26844843
Endocrine. 2017 Jan;55(1):303-306
pubmed: 26860513
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Horm Metab Res. 2016 Jul;48(7):440-5
pubmed: 27101095
Hypertens Res. 2016 Oct;39(10):681-687
pubmed: 27439492
Int J Mol Sci. 2018 Jan 30;19(2):null
pubmed: 29385702
Korean Circ J. 2018 Mar;48(3):198-208
pubmed: 29557106
Int J Genomics. 2018 Jan 21;2018:8576890
pubmed: 29607311
Endocrinol Jpn. 1981 Dec;28(6):735-9
pubmed: 7049681

Auteurs

Shigenori Nakamura (S)

Thyroid and Diabetic Division, Department of Internal Medicine, Japanese Red Cross Gifu Hospital, Japan.

Masatoshi Ishimori (M)

Thyroid and Diabetic Division, Department of Internal Medicine, Japanese Red Cross Gifu Hospital, Japan.

Noriyoshi Yamakita (N)

Department of Internal Medicine, Matsunami General Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH